a School of Pharmaceutical Sciences, Rajiv Gandhi Technical University , Bhopal , Madhya Pradesh , India.
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):274-283. doi: 10.1080/21691401.2017.1307210. Epub 2017 Apr 19.
RNA interference (RNAi)-based therapeutic approaches are under vibrant scrutinisation to seek cancer cure. siRNA suppress expression of the carcinogenic genes by targeting the mRNA expression. However, in vivo systemic siRNA therapy is hampered by the barriers such as poor cellular uptake, instability under physiological conditions, off-target effects and possible immunogenicity. To overcome these challenges, systemic siRNA therapy warrants the development of clinically suitable, safe, and effective drug delivery systems. Herein, we review the barriers, potential siRNA drug delivery systems, and application of siRNA in clinical trials for cancer therapy. Further research is required to harness the full potential of siRNA as a cancer therapeutic.
基于 RNA 干扰 (RNAi) 的治疗方法正在受到热烈关注，以期寻求癌症治疗方法。siRNA 通过靶向 mRNA 表达来抑制致癌基因的表达。然而，体内系统的 siRNA 治疗受到多种障碍的限制，例如细胞摄取能力差、生理条件下不稳定、脱靶效应和可能的免疫原性。为了克服这些挑战，系统的 siRNA 治疗需要开发临床适用、安全有效的药物递送系统。本文综述了系统给药的障碍、潜在的 siRNA 药物递送系统以及 siRNA 在癌症治疗临床试验中的应用。需要进一步的研究来充分发挥 siRNA 作为癌症治疗的潜力。
